Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Dyne Therapeutics Inc (DYN)

Dyne Therapeutics Inc (DYN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Insider Sale: Chief Scientific Officer of $DYN (DYN) Sells 2,334 Shares

Oxana Beskrovnaya, the Chief Scientific Officer of $DYN ($DYN), sold 2,334 shares of the company on 12-11-2024. We received data on the trade from a recent SEC filing. This was a sale of approximately...

DYN : 23.99 (-1.28%)
Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update

DYN : 23.99 (-1.28%)
Dyne Therapeutics to Present at Upcoming Investor Conferences

DYN : 23.99 (-1.28%)
Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE™ Platform to Address Underlying Causes of Neuromuscular Diseases

DYN : 23.99 (-1.28%)
2 Breakout Biotech Stocks With CEO Insider Buying

These two breakout stocks are on a stellar run higher on the charts, but should investors follow executives into the shares?

DYN : 23.99 (-1.28%)
RLMD : 0.3629 (+2.89%)
Chart of the Day: Dyne Therapeutics - Deeply Discounted

The Chart of the Day belongs to the biotechnology company Dyne Therapeutics (DYN) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals,...

DYN : 23.99 (-1.28%)
Why Shares of Dyne Therapeutics Fell This Week

Insiders sold more than 15,000 shares of company stock on Tuesday.

DYN : 23.99 (-1.28%)
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research

- FORCE™ Platform Achieves Enhanced Exon Skipping and Prolonged Dystrophin Restoration in Duchenne in vivo mdx Model - WALTHAM, Mass., Aug. 10, 2022 ...

DYN : 23.99 (-1.28%)
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

- Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 On Track for Mid-2022 - WALTHAM, Mass.,...

DYN : 23.99 (-1.28%)
Dyne Therapeutics Announces Clearance of Clinical Trial Application for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1

- Initiation of Dosing in Multiple Ascending Dose Clinical Trial of DYNE-101 in Patients with DM1 On Track for Mid-2022 - - Executing on Global Clinical...

DYN : 23.99 (-1.28%)

Barchart Exclusives

How To Profit From The Latest Corporate Spinoffs: A Guide For Investors In 2025
How to navigate corporate spinoffs. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar